Drugs like Ozempic, Mounjaro and Saxenda have swept the globe since emerging on the market late last decade, and an estimated 20,000 Australians currently use the drugs for weight loss.

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that ...

Find out all you need to know about Ozempic and other weight loss drugs, including the dangers and side effects ...

PEOPLE TAKING GLP-1S have a reduced risk of heart attacks, strokes, and death from cardiovascular disease, according to a ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

The company behind popular weight-loss drugs failed to disclose even more ... Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose ...

Saxenda contains liraglutide, which is a GLP-1 receptor agonist. Liraglutide helps promote weight loss by decreasing appetite and slowing the emptying of the stomach, which promotes feelings of ...

The company behind popular weight-loss drugs failed to disclose millions of pounds it paid to healthcare groups and patient ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...